| Market cap | $34.15B |
|---|---|
| Enterprise value | $23.19B |
| Revenue | $144.596B |
|---|---|
| EBITDA | $702.000M |
| Income | -$6.04 |
| Revenue Q/Q | 6.28% |
| Revenue Y/Y | 8.48% |
| P/E | N/A |
|---|---|
| Forward P/E | 3.45 |
| EV/Sales | 0.16 |
| EV/EBITDA | 33.04 |
| EV/EBIT | N/A |
| PEG | 13.02 |
| Price/Sales | 0.24 |
| P/FCF | N/A |
| Price/Book | 1.71 |
| Book/Share | 9.44 |
| Cash/Share | 0.00 |
| FCF yield | -5.17% |
| Volume | 19.133M / N/A |
|---|---|
| Relative vol. | N/A |
| EPS | N/A |
|---|---|
| EPS Q/Q | -31.62% |
| Est. EPS Q/Q | -32.74% |
| Profit margin | -2.21% |
|---|---|
| Oper. margin | -9.78% |
| Gross margin | 19.46% |
| EBIT margin | -4.71% |
| EBITDA margin | 0.49% |
| Ret. on assets | -6.40% |
|---|---|
| Ret. on equity | -32.61% |
| ROIC | -5.03% |
| ROCE | -11.48% |
| Debt/Equity | 3.40 |
|---|---|
| Net debt/EBITDA | 192.18 |
| Current ratio | 0.66 |
| Quick ratio | 0.32 |
| Volatility | 3.33% |
|---|---|
| Beta | 0.72 |
| RSI | 47.89 |
|---|
| Insider ownership | 17.31% |
|---|---|
| Inst. ownership | 59.48% |
| Shares outst. | 862.713M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 3.55% |
| Short ratio | 3.10 |
| Dividend | $1.46 |
|---|---|
| Dividend yield | 9.64% |
| Payout ratio | 256.06% |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 27 Jun 2024 |
Wednesday, 22 May 2024
|
|
| Walgreens further cuts stake in drug distributor Cencora | |
| S&P 500 Companies Boost Profit by Stripping More Items From Earnings | |
Monday, 13 May 2024
|
|
| Walgreens Stock Rallies On Report It's Booting UK Drugstores | |
Wednesday, 1 May 2024
|
|
| Investor Optimism Dampens as Walgreens Boots Alliance Struggles With Market Turbulence | |
Tuesday, 30 April 2024
|
|
| Walgreens Stock Lashed as Investors Left With ‘Nothing to Go On’ | |
Friday, 26 April 2024
|
|
| CVS Omnicare staff in Las Vegas vote to join new union | |
Thursday, 25 April 2024
|
|
| Walgreens Boots Alliance Declares Quarterly Dividend | |
Saturday, 20 April 2024
|
|
| 10 Best Healthcare Stocks to Buy Under $20 | |
Wednesday, 10 April 2024
|
|
| 10 Underperforming Stocks Insiders are Buying | |
Sunday, 7 April 2024
|
|
| Dollar Tree, Walgreens CFOs Snap Up the Stocks | |
Monday, 1 April 2024
|
|
| Walgreens Boots Alliance, Inc. Q2 2024 Earnings Call Transcript | |
Friday, 29 March 2024
|
|
| Decoding Walgreens Boots Alliance Inc : A Strategic SWOT Insight | |
Thursday, 28 March 2024
|
|
| US STOCKS-Equities poised to wrap up strong quarter on quiet note | |
| Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics | |
| Walgreens Boots Alliance Cuts Higher End Of 2024 Profit Outlook, Takes $5.8B Impairment Charge Related To VillageMD Business | |
| Walgreens narrows full-year profit forecast, takes $5.8-billion impairment | |
Sunday, 24 March 2024
|
|
| GameStop, Walgreens, Inflation Numbers, More to Watch This Week | |
Monday, 18 March 2024
|
|
| Delta Air Lines, Ford, GM, and Walgreens Are the Cheapest Stocks in the S&P 500 | |
Wednesday, 13 March 2024
|
|
| How AI-powered technologies can eventually eradicate retail crime | |
Monday, 11 March 2024
|
|
| UPDATE 1-Walgreens settles New York charges it grossly inflated prices of infant formula | |
Saturday, 9 March 2024
|
|
| 20 Biggest Retail Companies in the US | |
Friday, 8 March 2024
|
|
| 15 Worst Performing Stocks in S&P 500 | |
Thursday, 29 February 2024
|
|
| This Dow Jones Stock Is Not To Be Ignored. Why Doing So Would Be 'Misguided.' | |
Tuesday, 27 February 2024
|
|
| Walgreens First Community Pharmacy to Accept a Broad Array of Medicare Advantage Supplemental Benefits Online and in App | |
Wednesday, 21 February 2024
|
|
| US STOCKS-Futures dip ahead of high-stakes Nvidia results, Fed minutes | |
| These Stocks Are Moving the Most Today: Nvidia, Amazon, Palo Alto Networks, SolarEdge, Teladoc Health, and More | |
Tuesday, 20 February 2024
|
|
| Amazon to Replace Walgreens in Dow Jones Industrial Average | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Inderpal S Bhandari Director | Buy 11 Apr 2024 | $54,150 |
| Manmohan Mahajan EVP and Global CFO | Buy 2 Apr 2024 | $116,280 |
| Valerie B Jarrett Director | Buy 29 Jan 2024 | $99,993 |
| Nancy M Schlichting Director | Sale 16 Jan 2024 | $350,567 |
| Timothy C Wentworth Chief Executive Officer | Buy 5 Jan 2024 | $242,200 |
| Richard P. Gates SVP and Chief Pharmacy Officer | Sale 10 Nov 2023 | $20,450 |
| John Patrick Driscoll EVP and Pres. U.S. Healthcare | Buy 30 Jun 2023 | $146,988 |
| Rosalind G Brewer CEO | Buy 29 Mar 2023 | $339,500 |
| Kevin M. Ban EVP and Chief Medical Officer | Option 18 Nov 2022 | $350,714 |
| Nancy M Schlichting Director | Sale 17 Nov 2022 | $660,977 |
| Nancy M Schlichting Director | Sale 19 Nov 2021 | $128,511 |
Powered by
Robintrack.
Price target
Current $15.55
Average $39.83
Low $33
High $43
Dividends
| Ex-dividend date | N/A | Frequency | Quarterly | Annual dividend | +0.26% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 9.64% | Growth period | 37 years |
| Last dividend date | Yield 3 years | 7.37% | Growth 3 years | +1.25% | |
| Last dividend | Yield 5 years | 6.08% | Growth 5 years | +2.71% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Stefano Pessina (79) Executive Vice Chairman of the Board and Chief Executive Officer since 2015 | 79 | 2015 | $17,483,200 |
| Alexander Gourlay (59) Co-Chief Operating Officer since 2016 | 59 | 2016 | $10,999,500 |
| Ornella Barra (66) Co-Chief Operating Officer since 2016 | 66 | 2016 | $9,211,610 |
| James Skinner (76) Executive Chairman of the Board since 2015 | 76 | 2015 | $8,797,710 |
| James Kehoe (56) Global Chief Financial Officer and Executive Vice President since 2019 | 56 | 2019 | $8,656,420 |
| Rosalind Gates Brewer (59) CEO and Director | 59 | $8,133,450 | |
| Ornella Barra (68) Chief Operating Officer of International | 68 | $3,743,833 | |
| James Kehoe (59) Exec. VP and Global CFO | 59 | $2,901,867 | |
| John T. Standley (58) Exec. VP and Pres of Walgreens | 58 | $2,311,142 | |
| William Foote (69) Lead Independent Director since 1997 | 69 | 1997 | $460,000 |
| Janice Babiak (62) Independent Director since 2012 | 62 | 2012 | $325,000 |
| David Brailer (61) Independent Director since 2010 | 61 | 2010 | $320,000 |
| Nancy Schlichting (66) Independent Director since 2006 | 66 | 2006 | $319,969 |
| Dominic Murphy (53) Independent Director since 2012 | 53 | 2012 | $300,000 |
| John Lederer (65) Independent Director since 2015 | 65 | 2015 | $300,000 |
| Ginger Graham (65) Independent Director since 2010 | 65 | 2010 | $300,000 |
| Jose Almeida (58) Independent Director since 2017 | 58 | 2017 | $299,969 |
| Stefano Pessina (80) Exec. Chairman | 80 | $131,064 | |
| Pamela Puryear | 2020 | ||
| Valerie Jarrett (64) Independent Director since 2020 | 64 | 2020 | |
| John Standley (57) Executive Vice President and President - Walgreens since 2020 | 57 | 2020 | |
| Francesco Tinto | 2019 | ||
| Heather Dixon (47) Senior Vice President, Chief Accounting Officer, and Global Controller since 2019 | 47 | 2019 | |
| Marco Pagni (57) Executive Vice President, Chief Administrative Officer, and General Counsel since 2016 | 57 | 2016 | |
| Aaron C. Radelet | |||
| Danielle Carim Gray (43) Exec. VP and Global Chief Legal Officer | 43 | ||
| Gerald Gradwell (53) Sr. VP of Investor Relations | 53 | ||
| Manmohan Mahajan (42) Sr. VP, Global Controller, and Chief Accounting Officer | 42 |
walgreens boots alliance is the first global pharmacy-led, health and wellbeing enterprise. the company was created through the combination of walgreens and alliance boots in december 2014, bringing together two leading companies with iconic brands, complementary geographic footprints, shared values and a heritage of trusted health care services through pharmaceutical wholesaling and community pharmacy care, dating back more than 100 years. the company employs more than 370,000* people and has a presence in more than 25* countries; it is the largest retail pharmacy, health and daily living destination in the usa and europe. including its equity method investments, walgreens boots alliance is a global leader in pharmacy-led, health and wellbeing retail with over 13,100* stores in 11* countries. the company includes one of the largest global pharmaceutical wholesale and distribution networks with over 350* distribution centers delivering to more than 200,000** pharmacies, doctors, he
- Consumer Staples > Drug Retail
- Walgreens Boots Alliance Inc, 108 Wilmot Road, Deerfield 60015, United States
- 847 315 3700
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Quarterly | Annual dividend | +0.26% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 9.64% | Growth period | 37 years |
| Last dividend date | Yield 3 years | 7.37% | Growth 3 years | +1.25% | |
| Last dividend | Yield 5 years | 6.08% | Growth 5 years | +2.71% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $668 | $784 | |||
| Short term investments | |||||
| Net receivables | $6,200 | $5,972 | |||
| Inventory | $8,557 | $9,454 | |||
| Total current assets | $16,561 | $17,345 | |||
| Long term investments | $3,256 | $3,400 | |||
| Property, plant & equipment | $31,463 | $32,884 | |||
| Goodwill & intangible assets | $28,798 | $41,462 | |||
| Total noncurrent assets | $67,646 | $80,478 | |||
| Total investments | $3,256 | $3,400 | |||
| Total assets | $84,207 | $97,823 | |||
| Current liabilities | |||||
| Accounts payable | $12,775 | $13,593 | |||
| Deferred revenue | |||||
| Short long term debt | $4,276 | $4,020 | |||
| Total current liabilities | $24,915 | $26,116 | |||
| Long term debt | $29,347 | $29,717 | |||
| Total noncurrent liabilities | $43,928 | $43,950 | |||
| Total debt | $33,623 | $33,737 | |||
| Total liabilities | $68,843 | $70,066 | |||
| Stockholders' equity | |||||
| Retained earnings | $26,448 | $32,573 | |||
| Other stockholder equity | -$2,897 | -$2,995 | |||
| Total stockholder equity | $13,484 | $19,481 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1,358 | |||
| Short term investments | $1,114 | |||
| Net receivables | $5,381 | $5,017 | ||
| Inventory | $8,257 | $8,353 | ||
| Total current assets | $15,503 | $16,902 | ||
| Long term investments | $4,236 | $5,495 | ||
| Property, plant & equipment | $33,254 | $32,988 | ||
| Goodwill & intangible assets | $41,822 | $33,010 | ||
| Total noncurrent assets | $81,125 | $73,222 | ||
| Total investments | $4,236 | $6,609 | ||
| Total assets | $96,628 | $90,124 | ||
| Current liabilities | ||||
| Accounts payable | $12,635 | $11,255 | ||
| Deferred revenue | ||||
| Short long term debt | $3,264 | $3,345 | ||
| Total current liabilities | $24,535 | $22,583 | ||
| Long term debt | $30,269 | $32,132 | ||
| Total noncurrent liabilities | $43,605 | $37,134 | ||
| Total debt | $33,533 | $35,477 | ||
| Total liabilities | $68,140 | $59,717 | ||
| Stockholders' equity | ||||
| Retained earnings | $33,058 | $37,801 | ||
| Other stockholder equity | -$2,993 | -$2,805 | ||
| Total stockholder equity | $20,020 | $25,275 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $37,052 | $36,707 | |||
| Cost of revenue | $30,012 | $29,937 | |||
| Gross profit | $7,040 | $6,770 | |||
| Operating activities | |||||
| Research & development | |||||
| Selling, general & administrative | $7,921 | $6,851 | |||
| Total operating expenses | $20,211 | $6,809 | |||
| Operating income | -$13,171 | -$39 | |||
| Income from continuing operations | |||||
| EBIT | -$6,552 | -$42 | |||
| Income tax expense | -$782 | -$74 | |||
| Interest expense | $138 | $99 | |||
| Net income | |||||
| Net income | -$5,908 | -$67 | |||
| Income (for common shares) | -$5,908 | -$67 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $139,081 | $132,703 | ||
| Cost of revenue | $112,009 | $104,437 | ||
| Gross profit | $27,072 | $28,266 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $34,205 | $27,295 | ||
| Total operating expenses | $33,953 | $27,295 | ||
| Operating income | -$6,881 | $971 | ||
| Income from continuing operations | ||||
| EBIT | -$4,358 | $4,707 | ||
| Income tax expense | -$1,858 | -$30 | ||
| Interest expense | $580 | $400 | ||
| Net income | ||||
| Net income | -$3,080 | $4,337 | ||
| Income (for common shares) | -$3,080 | $4,337 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | -$5,908 | -$67 | |||
| Operating activities | |||||
| Depreciation | $614 | $616 | |||
| Business acquisitions & disposals | -$119 | -$109 | |||
| Stock-based compensation | $48 | $51 | |||
| Total cash flows from operations | -$637 | -$281 | |||
| Investing activities | |||||
| Capital expenditures | -$352 | -$506 | |||
| Investments | $300 | $427 | |||
| Total cash flows from investing | $817 | $85 | |||
| Financing activities | |||||
| Dividends paid | -$413 | -$415 | |||
| Sale and purchase of stock | -$69 | ||||
| Net borrowings | $274 | $205 | |||
| Total cash flows from financing | -$313 | $186 | |||
| Effect of exchange rate | $2 | ||||
| Change in cash and equivalents | -$132 | -$10 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$3,080 | $4,337 | ||
| Operating activities | ||||
| Depreciation | $2,257 | $1,990 | ||
| Business acquisitions & disposals | -$7,313 | -$2,189 | ||
| Stock-based compensation | $385 | $391 | ||
| Total cash flows from operations | $2,258 | $3,899 | ||
| Investing activities | ||||
| Capital expenditures | -$2,117 | -$1,734 | ||
| Investments | $1,767 | $1,308 | ||
| Total cash flows from investing | -$3,094 | -$1,064 | ||
| Financing activities | ||||
| Dividends paid | -$1,659 | -$1,659 | ||
| Sale and purchase of stock | -$105 | -$160 | ||
| Net borrowings | -$2,703 | $3,587 | ||
| Total cash flows from financing | -$887 | -$1,499 | ||
| Effect of exchange rate | $20 | -$47 | ||
| Change in cash and equivalents | -$1,702 | $1,288 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | State Street Corp |
-33.20%
|
36,193,755 | $785,042,546 |
| 2024 Q1 | Capital World Investors |
+57.52%
|
29,061,021 | $630,333,545 |
| 2024 Q1 | Proshare Advisors |
-85.72%
|
991,335 | $21,502,057 |
| 2024 Q1 | Morgan Stanley |
-25.69%
|
12,601,370 | $273,323,743 |
| 2024 Q1 | Thompson Siegel & Walmsley |
+1,211,291.20%
|
3,028,478 | $65,688 |
| 2024 Q1 | Jpmorgan Chase & Co |
+74.33%
|
6,229,199 | $135,111,326 |
| 2024 Q1 | Blackrock |
+3.40%
|
68,133,821 | $1,477,822,568 |
| 2024 Q1 | Amundi |
+138.05%
|
3,041,840 | $53,508,521 |
| 2024 Q1 | Invesco |
-9.16%
|
17,307,235 | $375,393,927 |
| 2024 Q1 | Fmr |
+151.92%
|
2,575,154 | $55,855,088 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Vanguard Group Inc | 10.05% | 86,675,198 | |
| Blackrock | 7.90% | 68,133,821 | |
| State Street Corp | 4.20% | 36,193,755 | |
| Capital World Investors | 3.37% | 29,061,021 | |
| Invesco | 2.01% | 17,307,235 | |
| Geode Capital Management | 1.92% | 16,560,044 | |
| Morgan Stanley | 1.46% | 12,601,370 | |
| Camber Capital Management L.P. | 0.90% | 7,800,000 | |
| Northern Trust Corp | 0.85% | 7,336,446 | |
| Legal & General PLC | 0.83% | 7,191,448 |
Sign up